We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Urine Test Uses Tiny Worms to Detect Early Signs of Cancer

By LabMedica International staff writers
Posted on 24 Nov 2021
Print article
Image: Nematodes used in N-NOSE (Photo courtesy of Hirotsu Bio Science)
Image: Nematodes used in N-NOSE (Photo courtesy of Hirotsu Bio Science)

Scientists have developed a screening test that uses tiny worms to detect early signs of cancer in urine that could help boost routine screening.

Scientists at Hirotsu Bio Science (Tokyo, Japan) have developed N-NOSE, a cancer screening test that uses highly sensitive olfactory sensory functions of genetically modified a type of worm called "C. elegans" (nematodes) with an acute sense of smell. N-NOSE, which stands for Nematode Nose, uses the chemotaxis characteristic of nematodes, i.e., attractive responses to an odor it likes and repulsive responses to an odor it does not like, as an indicator. Nematodes are known to respond to 15 types of cancer of the stomach, colorectal, lung, breast, pancreatic, liver, prostate, uterine, esophageal, gall bladder, bile duct, kidney, bladder, ovarian, and oral/pharyngeal.

C. elegans nematode is the first multicellular organism to have its entire genome sequenced and is a very popular model organism in biological research. The idea of using nematodes, live creatures, in cancer testing stems from the fact that they have superior olfactory sensors that no man-made device can come close to. Because it has no eyes or ears, it relies on smell to navigate its environment and detect food. C. elegans therefore has a well-developed sense of smell and about 1,200 types of olfactory receptor genes that are able to detect minute odors that machines cannot detect. The novel N-NOSE test that employs the worm’s natural capabilities is not invasive, causes no pain and can be used for early detection of cancer.

The test requires a small amount of urine and is inexpensive since nematodes are inexpensive to breed. Each nematode lays as many as 300 eggs and feeds on coliform bacterium E. coli, making it inexpensive to breed C. elegans populations. Currently available cancer diagnostic tests often do not detect incipient cancer and it has been thought very difficult to know the existence of cancer at an early stage. However, nematodes respond to the minute odor of cancer, which is undetectable with existing tests, and thus make it possible to predict risks. Early detection of cancers as early as Stages 0 and 1 is possible with N-NOSE according to clinical studies, and one test is able to detect cancers regardless of their locations. The simple, painless urine test is suitable as a cancer test for all generations, including children. The company believes that in future, children will take regular cancer screening tests to detect pre-symptomatic tumors.

Related Links:
Hirotsu Bio Science 

Platinum Supplier
SARS-CoV-2 Pooling Test
Extensive SARS-CoV-2 Pooling
Electrolyte Analyzer
CARELYTE-500 Series
5-Part Differential Hematology Analyzer
Abacus 5
3-Part Diff Auto Hematology Analyzer
Cellagon 3

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.